Real-world Implications of Botulinum Neurotoxin A Immunoresistance for Consumers and Aesthetic Practitioners: Insights from ASCEND Multidisciplinary Panel
1
Issued Date
2024-06-20
Resource Type
eISSN
21697574
Scopus ID
2-s2.0-85196648000
Journal Title
Plastic and Reconstructive Surgery - Global Open
Volume
12
Issue
6
Rights Holder(s)
SCOPUS
Bibliographic Citation
Plastic and Reconstructive Surgery - Global Open Vol.12 No.6 (2024)
Suggested Citation
Corduff N., Park J.Y., Calderon P.E., Choi H., Dingley M., Ho W.W.S., Martin M.U., Suseno L.S., Tseng F.W., Vachiramon V., Wanitphakdeedecha R., Yu J.N.T. Real-world Implications of Botulinum Neurotoxin A Immunoresistance for Consumers and Aesthetic Practitioners: Insights from ASCEND Multidisciplinary Panel. Plastic and Reconstructive Surgery - Global Open Vol.12 No.6 (2024). doi:10.1097/GOX.0000000000005892 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/99190
Title
Real-world Implications of Botulinum Neurotoxin A Immunoresistance for Consumers and Aesthetic Practitioners: Insights from ASCEND Multidisciplinary Panel
Author's Affiliation
Siriraj Hospital
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
Faculty of Medicine Ramathibodi Hospital, Mahidol University
The Specialists:
The Cosmetic Medicine Centre
Taoyuan Milano Aesthetic Clinic
Piena Clinic
Apkoo-Jung Oracle Dermatology Clinic
JY Dermatology and Aesthetic Center
St. Luke’s Medical Center
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
Faculty of Medicine Ramathibodi Hospital, Mahidol University
The Specialists:
The Cosmetic Medicine Centre
Taoyuan Milano Aesthetic Clinic
Piena Clinic
Apkoo-Jung Oracle Dermatology Clinic
JY Dermatology and Aesthetic Center
St. Luke’s Medical Center
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: As long-term, regular aesthetic botulinum neurotoxin A (BoNT-A) use becomes more commonplace, it is vital to understand real-world risk factors and impact of BoNT-A immunoresistance. The first Aesthetic Council on Ethical Use of Neurotoxin Delivery panel discussed issues relating to BoNT-A immunoresistance from the health care professionals’ (HCPs’) perspective. Understanding the implications of BoNT-A immunoresistance from the aesthetic patient’s viewpoint allows HCPs to better support patients throughout their aesthetic treatment journey. Methods: A real-world consumer study surveyed 363 experienced aesthetic BoNT-A recipients across six Asia-Pacific territories. The survey mapped participants’ BoNT-A aesthetic treatment journey and characterized awareness and attitudes relating to BoNT-A immunoresistance and treatment implications. At the second Aesthetic Council on Ethical use of Neurotoxin Delivery meeting, panelists discussed survey findings and developed consensus statements relating to the impact of BoNT-A immunoresistance on the aesthetic treatment journey. Results: Aesthetic BoNT-A patients’ depth of knowledge about BoNT-A immunoresistance remains low, and risk/benefit communications need to be more lay-friendly. The initial consultation is the most important touchpoint for HCPs to raise awareness of BoNT-A immunoresistance as a potential side effect considering increased risk with repeated high-dose treatments. HCPs should be cognizant of differences across BoNT-A formulations due to the presence of certain excipients and pharmacologically unnecessary components that can increase immunogenicity. Standardized screening for clinical signs of secondary nonresponse and a framework for diagnosing and managing immunoresistance-related secondary nonresponse were proposed. Conclusion: These insights can help patients and HCPs make informed treatment decisions to achieve desired aesthetic outcomes while preserving future treatment options with BoNT-A.